Peginterferon alfa-2b and ribavirin therapy in Kuwaiti patients with chronic hepatitis C virus infection;Traitement par peginterféron alfa-2b et ribavirine chez des patients koweïtiens atteints d'infection chronique par le virus de l'hépatite C

Eastern Mediterranean Health Journal

Volumn 17, Issue 8, 2011, Pages 669-678

  Al Enzi, S A ^a   Ismail, W A ^b   Alsurayei, S A ^a   Ismail, A E ^b  

^a FARWANIYA HOSPITAL   (Kuwait)

^b ZAGAZIG UNIVERSITY   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; ANEMIA; ANOREXIA; ANXIETY DISORDER; ARTHRALGIA; ARTICLE; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; GENETIC VARIABILITY; HAIR LOSS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INSOMNIA; KUWAIT; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MYALGIA; NAUSEA; NEUTROPENIA; PRURITUS; RASH; RELAPSE; RETROSPECTIVE STUDY; RISK FACTOR; SIDE EFFECT; THROMBOCYTOPENIA; THYROID DISEASE; VIRUS GENOME; VIRUS LOAD; WEIGHT REDUCTION;

EID: 80051971575     PISSN: 10203397     EISSN: None     Source Type: Journal    
DOI: 10.26719/2011.17.8.669     Document Type: Article

References (47)

1. World Health Organization. Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. Journal of Viral Hepatitis, 1999, 6:35-47.
2. Akbar HO. Hepatitis C virus infection in Saudi Arabia. Saudi Journal of Gastroenterology, 2004, 10:127-131.
3. Strader DB et al. American Association for the Study of Liver Diseases practice guideline: diagnosis, management, and treatment of hepatitis C. Hepatology, 2004, 39:1147-1171.
4. National Institutes of Health Consensus Development Conference Statement June 10-12, 2002. Management of hepatitis C: 2002. Hepatology, 2002, 36(Suppl. 1):S3-20.
5. Hofmann WP et al. Ribavirin mode of action in chronic hepatitis C: from clinical use back to molecular mechanisms. Liver International, 2008, 28:1332-1343.
6. Feld JJ, Hoofnagle JH. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature, 2005, 436:967-972.
7. Shiffman ML et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. New England Journal of Medicine, 2007, 357:124-134.
8. Yu MI et al. A randomized study of peginterferon and ribavirin for 16 weeks in patients with genotype 2 chronic hepatitis C. Gut, 2007, 56:553-559.
9. Seuzem S. Heterogenous virologic response rates to inter feron-based therapy in patients with chronic hepatitis C: who responds less well? Annals of Internal Medicine, 2004, 140:370-381.
10. Manns MP et al. Peginterferon a-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet, 2001, 358:958-965.
11. Hadziyannis SJ et al. Peginterferon alpha 2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Annals of Internal Medicine, 2004, 140:346-355.
12. Kamal SM et al. Peginterferon alpha-2b and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral kinetics on sustained virological response. Gut, 2005, 54:858-866.
13. Males S et al. Serum alpha-fetoprotein (AFP) level predicts treatment outcome in chronic hepatitis C. Antiviral Therapy, 2007, 12:797-803.
14. Osoba AO. Hepatitis C virus genotypes in Saudi Arabia. Saudi Medical Journal, 2002, 23:7-12.
15. Hu KQ, Vierling JK, Redeker AG. Viral host and interferon related factors modulating the effect of interferon therapy for hepatitis C virus infection. Journal of Viral Hepatitis, 2001, 8:1-18.
16. Bressler BL et al. High body mass index is an independent risk factor for non response to antiviral treatment in chronic hepatitis C. Hepatology, 2003, 38:557-559.
17. Distante S et al. Raised serum ferritin predicts non-response to interferon and ribavirin treatment in patients with chronic hepatitis C infection. Liver, 2002, 22:269-275.
18. Al-Ashgar H et al. Sustained virologic response to peginter feron alfa-2a and ribavirin in 335 patients with chronic hepatitis C: A tertiary care center experience. Saudi J Gastro, 2008, 14:58-65.
19. Pacsa AS et al. Genotypes of hepatitis C virus in Kuwait. Medical Principles and Practice, 2001, 10:55-57.
20. Varghese R et al. Treatment of chronic hepatitis C genotype 4 with peginterferon alpha-2a plus ribavirin. Hepato-Gastroenterology, 2009, 56:218-22.
21. Hasan F et al. Pegylated interferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4. American Journal of Gastroenterology, 2004, 99:1733-1737.
22. Koshy A et al. Treatment of hepatitis C virus genotype 4-related cirrhosis: ribavirin and interferon combination compared with interferon alone. Journal of Clinical Gastroenterology, 2002, 35:82-85.
23. Pang PS, Planet PJ, Dlenn JS. The evolution of the major hepatitis C genotypes correlates with clinical response to interferon therapy. PloS One, 2009, 4:e6579.
24. Mumtaz K et al. Distribution of hepatitis C genotypes and its response to treatment in Pakistani patients. Saudi Medical Journal, 2008, 29:1671-1673.
25. Zali MR et al. Hepatitis C virus genotypes in the Islamic Republic of Iran: a preliminary study. Eastern Mediterranean Health Journal, 2000, 6:372-377.
26. Ray SC et al. Genetic epidemiology of hepatitis C virus through out Egypt. Journal of Infectious Diseases, 2000, 182:698-707.
27. Cross TGS, Antoniades CG, Harrison PM. Current and future management of chronic hepatitis C infection. Postgraduate Medical Journal, 2008, 84:172-176.
28. Leung NW. Management of viral hepatitis C. Journal of Gastroenterology and Hepatology, 2002, 17(Suppl.):S146-S154.
29. Gad RR et al. Predictors of a sustained virological response in patients with genotype 4 chronic hepatitis C. Liver International, 2008, 28:1112-1119.
30. Roulot D et al. Epidemiological characteristics and response to peginterferon plus ribavirin treatment of hepatitis C virus genotype 4 infection. Journal of Viral Hepatitis, 2007, 14:460-467.
31. Xie Y et al. Predictive factors for sustained response to inter feron treatment in patients with chronic hepatitis C: a randomized, open, and multi-center controlled trial. Hepatobiliary and Pancreatic Diseases International, 2005, 4:213-219.
32. Kuboki M et al. Peginterferon a-2a (40 KD) plus ribvirin for the treatment of chronic hepatitis C in Japanese patients. Journal of Gastroenterology and Hepatology, 2007, 22:645-652.
33. Dev AT et al. Southeast Asian patients with chronic hepatitis C: the impact of novel genotypes and race on treatment outcome. Hepatology, 2002, 36:1259-1265.
34. Orito E. HCV genotype as a predictor of response to interferon therapy in patients with chronic hepatitis C. Japanese Journal of Clinical Medicine, 2001, 59:1356-1362.
35. Shobokshi OA, Serebour FE, Skakni LI. Hepatitis C genotypes/subtypes among chronic hepatitis patients in Saudi Arabia. Saudi Medical Journal, 2003, 24:S87-S91.
36. Chisari FV. Unscrambling hepatitis C virus-host interaction. Nature, 2005, 436:930-932.
37. Bybus OG et al. Genetic history of hepatitis C virus in East Asia. Journal of Virology, 2009, 83:1071-1082.
38. Kamal S. Improving outcome in patients with hepatitis C virus genotype 4. American Journal of Gastroenterology, 2007, 102:2582-2588.
39. Di Bisceglie AM et al. Early virologic response after peginter feron alpha-2a plus ribavirin or peginterferon alpha-2b plus ribavirin treatment in patients with chronic hepatitis C. Journal of Viral Hepatitis, 2007, 14:721-729.
40. Fried MW et al. Peginterferon a-2a plus ribavirin for chronic hepatitis C virus infection. New England Journal of Medicine, 2002, 347:975-982.
41. Shea DO et al. Role of rapid virological response in prediction of sustained virological response to Peg-IFN plus ribavirin in HCV/HIV co-infected individuals. Journal of Viral Hepatitis, 2008, 15:482-449.
42. Al-Shgar H et al. Predictors of sustained virological response to a 48-week course of pegylated interferon alfa-2a and ribavirin in patients infected with hepatitis C virus genotype 4. Annals of Saudi Medicine, 2009, 29:4-14.
43. Borgia G et al. Homocysteine levels and sustained virological response to pegylated-interferon a2b plus ribavirin therapy for chronic hepatitis C: a retrospective study. Liver International, 2009, 29:248-252.
44. Davis GL et al. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology (Baltimore, Md.), 2003, 38:645-652.
45. Ferenci P et al. Predicting sustained virological response in chronic hepatitis C patients treated with peginterferon alfa-2b (40KD)/ribavirin. Journal of Hepatology, 2005, 43:425-433.
46. Ferenci P. Predicting the therapeutic response in patients with chronic hepatitis C: the role of viral kinetic studies. Journal of Antimicrobial Chemotherapy, 2004, 53:15-18.
47. McHutchison JG et al. Predicting response to initial therapy with interferon plus ribavirin in chronic hepatitis C using serum HCV RNA results during therapy. Journal of Viral Hepatitis, 2001, 8:414-420.